Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Concise review: stem cells as an emerging platform for antibody therapy of cancer.

Frank RT, Najbauer J, Aboody KS.

Stem Cells. 2010 Nov;28(11):2084-7. doi: 10.1002/stem.513. Review.

2.

Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.

Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T, Metz MZ, Kim SU, Glackin CA, Wu AM, Yazaki PJ, Aboody KS.

PLoS One. 2009 Dec 15;4(12):e8314. doi: 10.1371/journal.pone.0008314.

3.

Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy.

Zhang Q, Chen G, Liu X, Qian Q.

Cell Res. 2007 Feb;17(2):89-99. Review.

4.

Possible applications of antibodies or their genes in cancer therapy.

Kuroki M, Huang J, Shibaguchi H, Tanaka T, Zhao J, Luo N, Hachimine K, Kinugasa T, Maekawa S, Enatsu S, Hamanaka W, Fukami T, Kuroki M.

Anticancer Res. 2006 Nov-Dec;26(6A):4019-25. Review.

5.

Stem cells and frontiers of therapeutic advances in cancer.

Chaudhuri S, Law S.

J Exp Clin Cancer Res. 2005 Jun;24(2):165-73. Review.

PMID:
16110747
6.

Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives.

Zangemeister-Wittke U.

Pathobiology. 2005;72(6):279-86. Review.

PMID:
16582579
7.

Cancer stem cell biology: from leukemia to solid tumors.

Jordan CT.

Curr Opin Cell Biol. 2004 Dec;16(6):708-12. Review.

PMID:
15530785
8.

Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?

Deonarain MP, Kousparou CA, Epenetos AA.

MAbs. 2009 Jan-Feb;1(1):12-25. Review.

9.

New approaches to antibody therapy.

Weiner LM, Adams GP.

Oncogene. 2000 Dec 11;19(53):6144-51. Review.

10.

Stem cells, melanoma and cancer stem cells: the good, the bad and the evil?

Menaa F, Houben R, Eyrich M, Broecker EB, Becker JC, Wischhusen J.

G Ital Dermatol Venereol. 2009 Jun;144(3):287-96. Epub 2008 Dec 17. Review.

PMID:
19088701
11.

Monoclonal antibody-based therapy.

von Mehren M, Weiner LM.

Curr Opin Oncol. 1996 Nov;8(6):493-8. Review.

PMID:
8971469
12.

Universal and stemness-related tumor antigens: potential use in cancer immunotherapy.

Parmiani G, Russo V, Marrari A, Cutolo G, Casati C, Pilla L, Maccalli C, Rivoltini L, Castelli C.

Clin Cancer Res. 2007 Oct 1;13(19):5675-9. No abstract available.

13.
14.

First among equals: the cancer cell hierarchy.

Ichim CV, Wells RA.

Leuk Lymphoma. 2006 Oct;47(10):2017-27. Review.

PMID:
17071472
15.

Cytophilic antibody and cancer therapy: review and postulate.

Berken A.

N Y State J Med. 1979 May;79(6):849-52. No abstract available.

PMID:
286183
16.

Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.

Kuroki M, Hachimine K, Huang J, Shibaguchi H, Kinugasa T, Maekawa S, Kuroki M.

Anticancer Res. 2005 Nov-Dec;25(6A):3725-32. Review.

17.

Biological impediments to monoclonal antibody-based cancer immunotherapy.

Christiansen J, Rajasekaran AK.

Mol Cancer Ther. 2004 Nov;3(11):1493-501. Review.

18.

New hope in the horizon: cancer stem cells.

Bhattacharyya S, Khanduja KL.

Acta Biochim Biophys Sin (Shanghai). 2010 Apr;42(4):237-42. Review.

PMID:
20383470
19.

Review of stem cell deregulation and breast cancer: an emerging hypothesis.

Kumar DH, Kutty MK.

Indian J Pathol Microbiol. 2012 Apr-Jun;55(2):147-53. doi: 10.4103/0377-4929.97842. Review.

20.

Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.

Bodey B, Siegel SE, Kaiser HE.

Anticancer Res. 1996 Mar-Apr;16(2):661-74. Review.

PMID:
8687112

Supplemental Content

Support Center